Nanotechnology-based Systems Research Articles

Nanotechnology-based approaches for targeted drug delivery for the treatment of respiratory tract infections

Background: Nanotechnology has emerged as a promising field for the diagnosis, monitoring, and treatment of respiratory tract infections (RTIs). By leveraging the unique properties of nanoscale delivery systems, nanotechnology can significantly enhance the selectivity and efficacy of antimicrobials, thereby reducing off-target effects. Objective: This review explores the development and application of targeted nanosystems in combating viral, bacterial, and fungal RTIs. Nanotechnology-based systems, including biological and non-biological nanoparticles, offer innovative solutions for overcoming antimicrobial resistance, improving drug bioavailability, and minimizing systemic side effects. RTIs are a leading cause of morbidity and mortality globally, particularly affecting vulnerable populations such as children, the elderly, and immunocompromised individuals. Traditional drug delivery methods face numerous challenges, such as rapid clearance, poor tissue penetration, and drug degradation. Nanoparticle-based delivery systems address these issues by enhancing tissue penetration, providing sustained drug release, and enabling targeted delivery to infection sites. These systems include liposomal delivery, polymeric nanoparticles, dendrimers, and metal-based nanoparticles, each offering unique advantages in treating RTIs. Nanotechnology also plays a crucial role in vaccine development by offering new strategies to enhance immune responses and improve antigen delivery. Furthermore, the review discusses the clinical translation and regulatory considerations for nanotechnology-based drug delivery, emphasizing the need for rigorous testing and quality control to ensure safety and efficacy. Conclusion: Nanotechnology offers promising advancements in the treatment, and prevention of RTIs by enhancing drug delivery and efficacy. By addressing challenges such as antimicrobial resistance and poor tissue penetration, nanotechnology-based systems have the potential to significantly improve patient outcomes.

Advanced Nanotechnological Approaches for Biofilm Prevention and Control

Biofilm-associated infections present a significant challenge in modern medicine, primarily due to their resilience and resistance to conventional treatments. These infections occur when bacteria form biofilms, protective layers formed by bacterial communities, which are notoriously resistant to traditional antibiotics on surfaces such as medical implants and biological surfaces, making eradication with standard antibiotics difficult. This resilience leads to persistent infections, imposing a substantial economic burden on healthcare systems. The urgency to find alternative treatments is critical as current methods are insufficient and costly. Innovative approaches, such as nanotechnology-based therapies, offer promising alternatives by targeting biofilms more effectively and reducing the need for invasive procedures. Nanocarriers hold significant promise in the fight against biofilm-associated infections. Nanocarriers can penetrate biofilms more effectively than conventional treatments, delivering higher concentrations of antibiotics or other antimicrobial agents precisely where they are needed. This targeted approach not only enhances the efficacy of treatments but also minimizes potential side effects. The development of nanocarrier-based therapies is crucial for overcoming the limitations of current treatments and ultimately improving patient outcomes and reducing the economic burden of biofilm-associated infections on healthcare systems. In this review, nanotechnology-based systems, their characteristics, limitations, and potential benefits are explored to address biofilms-related infections. Additionally, biofilm evaluation models and the tests necessary for the preclinical validation of these nanosystems to facilitate their clinical application are addressed.

Design of ternary reversible Feynman and Toffoli gates in ternary quantum-dot cellular automata

The use of reversible logic gates leads to a reduction in energy loss in logic circuits by preventing information loss. New computing methods, such as quantum-dot cellular automata (QCA), have been offered by nanotechnology emerging with nanoelectronics to make more comprehensive logic circuits. In nanotechnology-based systems, some bits are erased when the system performs any computation, and this causes heat dissipation and energy loss in systems. Adder circuits are the basis of any arithmetic operation and one of the main parts of many circuits for creating complex hardware; therefore, the use of enhanced adder circuits leads to high performance in logic circuits. In irreversible logic, the energy that is transferred from the power supply to the circuit is converted into heat, and energy loss occurs. Power management plays a vital role in modern computational systems, and using ternary logic instead of previous technologies leads to better performance. The main purpose of our study is to design ternary quantum-dot cellular automata (TQCA) reversible logic gates based on ternary quantum-dot cellular technology. Reversible gates are the basis of creating a reversible circuit. In this paper, the Muthukrishnan-Stroud (M-S) gate, which is the basis of all other reversible ternary gates, is implemented in ternary QCA technology, and then, reversible ternary Feynman and Toffoli (C2NOT) gates are designed. More optimal adder circuits can be realized in three-valued technology using Feynman and Toffoli gates. The area, delay, and cell count of the proposed TQCA designs are compared with those of other related works, and the effect of fault on the designs in the presence of cell omission defect is determined. The occupied areas of the proposed Feynman and Toffoli gate designs are 0.069 μm2 and 0.073 μm2, respectively. Moreover, the fault tolerance levels of these TQCA gates are 77% and 92%, respectively.

Advancing Ocular Medication Delivery with Nano-Engineered Solutions: A Comprehensive Review of Innovations, Obstacles, and Clinical Impact.

Recent advancements in ocular drug delivery have led to the introduction of a range of nanotechnology-based systems, such as polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, inorganic nanoparticles, niosomes, liposomes, nanosuspensions, dendrimers, nanoemulsions, and microemulsions. These systems enhance drug retention, penetration, bioavailability, and targeted delivery, promising prolonged drug release, and improved patient compliance. However, their interactions with biological systems pose potential toxicity risks, necessitating a careful evaluation of nanoparticle size, shape, surface charge, and coating. Traditional ocular drug delivery methods, like topical applications and injections, face challenges due to anatomical and physiological barriers, leading to frequent dosing and systemic toxicity risks. Nanocarriers offer solutions by improving drug permeation and targeted delivery, yet translating these innovations from research to clinical practice involves overcoming hurdles related to manufacturing scale-up, quality control, regulatory approval, and cost-effectiveness. The quality by design (QbD) framework provides a systematic approach to optimize nanocarrier formulation and process design, ensuring safety and efficacy. Assessing the safety of nanocarriers through in vivo and in vitro studies is crucial for their clinical application. This review explores the use of various nanomedicines in ocular drug delivery, highlighting the current state of ocular medication delivery and considering critical aspects such as scaling up and clinical applications.

Investigations of nanomaterial-based membranes for efficient removal of contaminants from wastewater via membrane distillation: a critical review

The requirement for wastewater treatment is paramount in ensuring environmental sustainability and safeguarding public health. As industrialization and urbanization accelerate, the volume of wastewater generated continues to increase, containing a diverse range of pollutants and contaminants. Untreated wastewater poses serious threats to ecosystems, water bodies, and human communities, leading to pollution, waterborne diseases, and ecological imbalances. Effective wastewater treatment becomes essential to mitigate these adverse effects by removing or reducing pollutants before discharge into natural water sources. This process helps to preserve water quality, protect aquatic life, and maintain the overall health of ecosystems. Membrane distillation (MD) has emerged as a promising technology for wastewater treatment, offering an innovative approach to address the challenges associated with conventional treatment methods. In MD, a hydrophobic membrane serves as a selective barrier, allowing water vapor to pass through while preventing the passage of contaminants. This paper offers an extensive overview of the latest advancements in nanotechnology and membrane distillation applied in wastewater treatment. We will delve into different types of nanomaterials that have been used to enhance the properties of MD membranes, such as nanocomposites, nanoparticles, and nanofiber membranes. We also explore the mechanisms by which these nanomaterials improve the separation efficiency, anti-fouling properties, and durability of MD membranes. Additionally, we highlight the potential of hybrid membranes that combine different types of nanomaterials for further improving the performance of MD in wastewater treatment. We provide examples of recent studies that have investigated the use of hybrid membranes, including carbon nanotube-graphene oxide hybrid membranes, nanocomposite nanofiber membranes, and silver nanoparticle-embedded membranes. We also identify some areas for future research and development, such as the scale-up and commercialization of nanotechnology-based MD systems. In summary, this review paper highlights the potential of nanotechnology to enhance the performance of MD in wastewater treatment, leading to improved water quality and a cleaner environment.

Biopolymer Drug Delivery Systems for Oromucosal Application: Recent Trends in Pharmaceutical R&D.

Oromucosal drug delivery, both local and transmucosal (buccal), is an effective alternative to traditional oral and parenteral dosage forms because it increases drug bioavailability and reduces systemic drug toxicity. The oral mucosa has a good blood supply, which ensures that drug molecules enter the systemic circulation directly, avoiding drug metabolism during the first passage through the liver. At the same time, the mucosa has a number of barriers, including mucus, epithelium, enzymes, and immunocompetent cells, that are designed to prevent the entry of foreign substances into the body, which also complicates the absorption of drugs. The development of oromucosal drug delivery systems based on mucoadhesive biopolymers and their derivatives (especially thiolated and catecholated derivatives) is a promising strategy for the pharmaceutical development of safe and effective dosage forms. Solid, semi-solid and liquid pharmaceutical formulations based on biopolymers have several advantageous properties, such as prolonged residence time on the mucosa due to high mucoadhesion, unidirectional and modified drug release capabilities, and enhanced drug permeability. Biopolymers are non-toxic, biocompatible, biodegradable and may possess intrinsic bioactivity. A rational approach to the design of oromucosal delivery systems requires an understanding of both the anatomy/physiology of the oral mucosa and the physicochemical and biopharmaceutical properties of the drug molecule/biopolymer, as presented in this review. This review summarizes the advances in the pharmaceutical development of mucoadhesive oromucosal dosage forms (e.g., patches, buccal tablets, and hydrogel systems), including nanotechnology-based biopolymer nanoparticle delivery systems (e.g., solid lipid particles, liposomes, biopolymer polyelectrolyte particles, hybrid nanoparticles, etc.).

Nanotechnology: A promising tool for targeted drug delivery

Nanotechnology has eventually and strongly engaged in the field of drug delivery. It makes use of the specific properties of the substance at the Nano scale. Their primary goal is to increase therapeutic effects while reducing adverse effects. Due to their improved goods, nanotechnology has become more popular across a variety of industries. The term “Nano medicine” is used to denote the application of nanotechnology in medicine. This Nano medicine is essential for drug delivery, antibacterial, vaccine development, wearable technology, diagnostic and imaging tools, implants, high throughput screening platforms, etc. It makes use of biological, biomimetic, no biological, or hybrid materials. To attain logical drug delivery, it is important to understand the interlink age between nanoparticles and the biological environment, drug release, and targeting cell-surface receptors. We can control disease progression by using nanomaterial including peptide-based nanotubes to prey the vascular endothelial growth factor (VEGF) receptor. Also, the use of herbal medicine has been used since ancient times. The supply of active compounds is shown by the effectiveness of various species of herbal medicine. The essential requirements for extending novel nanotechnology-based medication delivery systems are highlighted in this review.

DNA nanotechnology-based nucleic acid delivery systems for bioimaging and disease treatment.

Nucleic acids, including DNA and RNA, have been considered as powerful and functional biomaterials owing to their programmable structure, good biocompatibility, and ease of synthesis. However, traditional nucleic acid-based probes have always suffered from inherent limitations, including restricted cell internalization efficiency and structural instability. In recent years, DNA nanotechnology has shown great promise for the applications of bioimaging and drug delivery. The attractive superiorities of DNA nanostructures, such as precise geometries, spatial addressability, and improved biostability, have enabled them to be a novel category of nucleic acid delivery systems for biomedical applications. In this review, we introduce the development of DNA nanotechnology, and highlight recent advances of DNA nanostructure-based delivery systems for cellular imaging and therapeutic applications. Finally, we propose the challenges as well as opportunities for the future development of DNA nanotechnology in biomedical research.

Design of nanoparticle-based systems for the systemic delivery of chemotherapeutics: Alternative potential routes via sublingual and buccal administration for systemic drug delivery.

Conventional therapeutic approaches for cancer generally involve chemo- and radiation therapies that often exhibit low efficacy and induce toxic side effects. Recent years have seen significant advancements in the use of protein biologics as a promising alternative treatment option. Nanotechnology-based systems have shown great potential in providing more specific and targeted cancer treatments, thus improving upon many of the limitations associated with current treatments. The unique properties of biomaterial carriers at the nanoscale have been proven to enhance both the performance of the incorporated therapeutic agent and tumor targeting; however, many of these systems are delivered intravenously, which can cause hazardous side effects. Buccal and sublingual delivery systems offer an alternative route for more efficient delivery of nanotechnologies and drug absorption into systemic circulation. This review concentrates on emerging buccal and sublingual nanoparticle delivery systems for chemo- and protein therapeutics, their development, efficacy, and potential areas of improvement in the field. Several factors contribute to the development of effective buccal or sublingual nanoparticle delivery systems, including targeting efficiency of the nanoparticulate carriers, drug release, and carrier biocompatibility. Furthermore, the potential utilization of buccal and sublingual multilayer films combined with nanoparticle chemotherapeutic systems is outlined as a future avenue for in vitro and in vivo research.

Synergistic effects of multidrug/material combination deliver system for anti-mutidrug-resistant tumor

Multidrug resistance (MDR) is a public health issue of particular concern, for which nanotechnology-based multidrug delivery systems are considered among the most effective suppressive strategies for such resistance in tumors. However, for such strategies to be viable, the notable shortcomings of reduced loading efficiency and uncontrollable drug release ratio need to be addressed. To this end, we developed a novel “multidrug/material” co-delivery system, using d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS, P-gp efflux pump inhibitor) and poly(amidoamine) (PAMAM) to fabricate a precursor material with the properties of reversing MDR and having a long-cycle. Further, to facilitate multidrug co-delivery, we loaded doxorubicin(Dox) and curcumin(Cur, cardiotoxicity modifier and P-gp inhibitor) into PAMAM-TPGS nano-micelles respectively, and mixed in appropriate proportions. The multidrug/material co-delivery system thus obtained was characterized by high drug loading and a controllable drug release ratio in the physiological environment. More importantly, in vitro and in vivo pharmacodynamic studies indicated that the multidrug/material co-delivery system facilitated the reversal of MDR. Moreover, the system has increased anti-tumor activity and is biologically safe. We accordingly propose that the “multidrug/material” co-delivery system developed in this study could serve as a potential platform for reversing MDR and achieving safe and effective clinical treatment.

Recent Advances in Nanocarrier Based Therapeutic and Diagnostic Approaches in Tuberculosis

<img src=” https://s3.amazonaws.com/production.scholastica/article/90699/large/prnano_1072023gaf.jpg?1701882189”> Tuberculosis is the second most fatal infectious disease; each year, it causes millions of deaths worldwide. Although several anti-TB drugs are currently available, the problem with these drugs is that they require a prolonged duration of treatment, with high drug doses. In addition, patient non-adherence to therapy subsequently leads to the development of multidrug-resistant and ex-tensively drug-resistant tuberculosis. Therefore, we need to develop an effective and robust nano-carrier-based drug delivery system to overcome these issues and improve the therapeutic potential of drug dose/duration and patient compliance. This review article focuses on the cur-rently available various nanotechnology-based therapeutic approaches, including lipid nanopar-ticles, polymeric particles, carbon nanotubes, glucan, and alginate-based nano-carrier systems for effective anti-TB drug delivery to host macrophage for mycobacterium killing. Finally, we also present some promising recent nanotechnology-based mycobacterial detection systems us-ing silver nanoparticles, silica nanoparticles, magnetic nanoparticles, quantum dots, and magnet-ic barcode assay that have recently emerged as the latest diagnostic tool. Functionalized nano-materials for emerging Aggregation-induced photodynamic therapy as next-generation theranostics have also been discussed as a novel option for TB diagnosis and therapy.

Thermo-responsive liposome nano-vesicles for co-delivery of emamectin benzoate and nitenpyram with synergistic pest control

The conventional pesticide formulations often suffer from low utilization rates and trigger the development of resistance, leading to significant resource waste and ecological damage. A promising solution to these issues lies in the design of intelligent, nanotechnology-based systems for controlled-release and co-delivery of pesticides. A multi-compartment liposome nano-vesicle (Co-EM-Lip) that simultaneously carries emamectin benzoate (EB) and nitenpyram (Nit) has been developed, using a eutectic mixture (EM) of fatty acids as a temperature-sensitive “switch”. This Co-EM-Lip system successfully enabled the co-delivery of two pesticides with differing water solubility and insecticidal pathways, along with a thermo-responsive controlled release. The effectiveness of Co-EM-Lip against Plutella xylostella was approximately 4.4 times higher at 35 °C than at 15 °C, which is attributable to high temperature-triggered rapid release properties. Importantly, EB and Nit within Co-EM-Lip demonstrated synergistic biological effects against various pests. Additionally, Co-EM-Lip showed less toxicity to zebrafish. This research thus introduces a novel strategy to devise smart, controlled-release and co-delivery pesticide systems aimed at enhancing pesticide efficiency, delaying pest resistance, and minimizing environmental harm and impact on non-target organisms.

Applications of Nanomedicine in Brain Tumor Therapy: Nanocarrierbased Drug Delivery Platforms, CChallenges, and Perspectives.

The most difficult kind of cancer to treat is brain cancer, which causes around 3% of all cancer-related deaths. The targeted delivery is improved with the use of technologies based on nanotechnology that are both safe and efficient. Because of this, there is now a lot of research being done on brain cancer treatments based on nanoformulations. In this review, the author's primary aim is to elucidate the various nanomedicine for brain cancer therapy. The authors focus primarily on the advancement of nanotechnology in treating brain cancer (BC). This review article gives readers an up-to-date look at publications on sophisticated nanosystems in treating BC, including quantum dots (QDs), nanoparticles (NPs), polymeric micelles (PMs), dendrimers, and solid lipid nanoparticles (SLNs), among others. This article offers insight into the use of various nanotechnology-based systems for therapy as well as their potential in the future. This article also emphasizes the drawbacks of nanotechnology-based methods. Future perspectives for treating brain cancer using proteomics and biomimetic nanosystems are briefly discussed. In this review, we review several aspects of brain cancer therapy, including various nanomedicines, their challenges and future perspectives. Overall, this article gives a thorough overview of both the present state of brain cancer treatment options and the disease itself.

Recent advances in nanocarrier-based drug delivery systems in treatment of rheumatoid arthritis

Rheumatoid arthritis(RA) is a widely prevalent autoimmune inflammatory disease that severely affects patients' quality of life. Currently, conventional formulations against RA have several limitations, such as nonspecificity, poor efficacy, large drug dosages, frequent administration, and systemic side effects. Nanotechnology-based drug delivery systems have emerged as a promising stra-tegy for the diagnosis and treatment of RA since nanotechnology can overcome the limitations of traditional treatments and simplify the complexity of the disease. These systems enable targeted delivery of anti-inflammatory drugs to the inflamed areas through active and passive targeting, achieving specificity to the joints, overcoming the need for increased dosage and administration frequency, and reducing associated adverse reactions. This article aimed to review nanocarrier-based drug delivery systems in the field of RA and elucidate how nanosystems can be utilized to deliver therapeutic drugs to inflamed joints for controlling RA progression. By discussing the current issues and challenges faced by nanodrug delivery systems and highlighting the urgent need for solutions, this article offers theoretical support for further research on nanotechnology-based co-delivery systems in the future.

Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation.

Glioblastoma multiforme (GBM) is the deadliest brain tumor with a poor prognosis and limited therapeutic options. Temozolomide (TMZ) is the first-line chemotherapeutic agent used for the treatment of GBM; however, it suffers from several limitations, including short half-life, rapid metabolism, <1% brain bioavailability, methyl guanine methyl transferase (MGMT) based chemoresistance, and hematological toxicities. Several approaches have been adopted to overcome these limitations, particularly by using nanotechnology-based systems, but its physicochemical properties make TMZ challenging to load into these nanocarriers. In the current research, we conjugated TMZ with different fatty acids, i.e., linoleic acid (LA), oleic acid (OA), and palmitic acid (PA), to obtain TMZ-fatty acid conjugates, which are comparatively hydrophobic, less prone to degradation and potent. These conjugates were thoroughly characterized using 1H NMR spectroscopy, high-resolution mass spectrometry (HR-MS), and reverse phase-high performance liquid chromatography (RP-HPLC). The synthesized conjugates, namely Temozolomide-oleic acid (TOA,6R1), Temozolomide-linoleic acid (TLA, 6R2), and Temozolomide-palmitic acid (TPA, 6R3), showed an IC50 of 101.4, 67.97, and 672.04μM, respectively in C6 cells and 428.257, 366.43 and 413.69μM, respectively in U87-MG cells. On the other hand, the free TMZ showed an IC50 of >1000μM and 564.23μM in C6 and U87-MG, respectively. Further, the in vivo efficacy of the TMZ-fatty acid conjugates was evaluated in the C6-induced orthotropic rat glioblastoma model, wherein the TMZ-fatty acid conjugate showed improved survival rate (1.6 folds) and overall health of the animals. Collectively, the conjugation of fatty acids with TMZ improves its anticancer potential against glioblastoma multiforme (GBM).

A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma

Melanoma, a malignant form of skin cancer, has been swiftly increasing in recent years. Although there have been significant advancements in clinical treatment underlying a well-understanding of melanoma-susceptible genes and the molecular basis of melanoma pathogenesis, the permanency of response to therapy is frequently constrained by the emergence of acquired resistance and systemic toxicity. Conventional therapies, including surgical resection, chemotherapy, radiotherapy, and immunotherapy, have already been used to treat melanoma and are dependent on the cancer stage. Nevertheless, ineffective side effects and the heterogeneity of tumors pose major obstacles to the therapeutic treatment of malignant melanoma through such strategies. In light of this, advanced therapies including nucleic acid therapies (ncRNA, aptamers), suicide gene therapies, and gene therapy using tumor suppressor genes, have lately gained immense attention in the field of cancer treatment. Furthermore, nanomedicine and targeted therapy based on gene editing tools have been applied to the treatment of melanoma as potential cancer treatment approaches nowadays. Indeed, nanovectors enable delivery of the therapeutic agents into the tumor sites by passive or active targeting, improving therapeutic efficiency and minimizing adverse effects. Accordingly, in this review, we summarized the recent findings related to novel targeted therapy methods as well as nanotechnology-based gene systems in melanoma. We also discussed current issues along with potential directions for future research, paving the way for the next-generation of melanoma treatments.

An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management.

Tuberculosis (TB), one of the deadliest contagious diseases, is a major concern worldwide. Long-term treatment, a high pill burden, limited compliance, and strict administration schedules are all variables that contribute to the development of MDR and XDR tuberculosis patients. The rise of multidrug-resistant strains and a scarcity of anti-TB medications pose a threat to TB control in the future. As a result, a strong and effective system is required to overcome technological limitations and improve the efficacy of therapeutic medications, which is still a huge problem for pharmacological technology. Nanotechnology offers an interesting opportunity for accurate identification of mycobacterial strains and improved medication treatment possibilities for tuberculosis. Nano medicine in tuberculosis is an emerging research field that provides the possibility of efficient medication delivery using nanoparticles and a decrease in drug dosages and adverse effects to boost patient compliance with therapy and recovery. Due to their fascinating characteristics, this strategy is useful in overcoming the abnormalities associated with traditional therapy and leads to some optimization of the therapeutic impact. It also decreases the dosing frequency and eliminates the problem of low compliance. To develop modern diagnosis techniques, upgraded treatment, and possible prevention of tuberculosis, the nanoparticle-based tests have demonstrated considerable advances. The literature search was conducted using Scopus, PubMed, Google Scholar, and Elsevier databases only. This article examines the possibility of employing nanotechnology for TB diagnosis, nanotechnology-based medicine delivery systems, and prevention for the successful elimination of TB illnesses.

Nanotechnology and CRISPR/Cas9 system for sustainable agriculture.

The clustered regularly interspaced short palindromic repeats (CRISPR-Cas9), a genome editing tool, has gained a tremendous position due to its therapeutic efficacy, ability to counteract abiotic/biotic stresses in plants, environmental remediation and sustainable agriculture with the aim of food security. This is mainly due to their potential of precised genome modification and numerous genetic engineering protocols with versatility as well as simplicity. This technique is quite useful for crop refinement and overcoming the agricultural losses and regaining the soil fertility hampered by hazardous chemicals. Since CRISPR/Cas9 has been widely accepted in genome editing in plants, however, their revolutionised nature and progress enable genetic engineers to face numerous challenges in plant biotechnology. Therefore, nanoparticles have addressed these challenges and improved cargo delivery and genomic editing processes. Henceforth, this barrier prevents CRISPR-based genetic engineering in plants in order to show efficacy in full potential and eliminate all the barriers. This advancement accelerates the genome editing process and its applications in plant biotechnology enable us to sustain and feed the massive population under varying environments. Genome editing tools using CRISPR/Cas9 and nanotechnology are advantageous that produce transgenic-free plants that overcome global food demands. Here, in this review, we have aimed towards the mechanisms/delivery systems linked with CRISPR/Cas9 system. We have elaborated on the applications of CRISPR/Cas9 and nanotechnology-based systems for sustainable agriculture. Moreover, the challenges and limitations associated with genome editing and delivery systems have also been discussed with a special emphasis on crop improvement.

Selective Nanoblocker of Cellular Stress Response for Improved Drug-Free Tumor Therapy.

Nanotechnology-based drug-free therapeutic systems using external stimuli can avoid the inherent side effects of drugs and become an attractive therapeutic strategy. However, the cellular stress responses (CSR) are activated encounter with external stimuli, which greatly weaken the efficacy of the drug-free antitumor. Thus, this work proposes a CSR regulation strategy and synthesizes the glucose oxidase (GOx)-modified Cu3 BiS3 nanosheets (CBSG NSs) encapsulated by calcium carbonate (CBSG@CaCO3 ) as the novel drug-free nanoagent. The CBSG@CaCO3 not only cause external stimuli such as energy consumption and oxidative stress damage, but also can destroy the CSR mechanism to guarantee optimal efficacy of starvation-chemodynamic therapy (ST-CDT). In tumor cells, the CaCO3 shell layer of CBSG@CaCO3 is rapidly degraded, releasing the slowly degradable CBSG NSs with NIR-II photothermal properties that accelerate the production of external stimuli under laser irradiation. Meanwhile, CaCO3 can block CSR to disrupt the adaptive viability of cancer cells by inhibiting expression of P27 and NRF2. Importantly, the CSR regulation achieves selective treatment on tumor cells based on the difference in physiological conditions between cancer cells and normal cells. This drug-free cancer therapy with selectivity improves the problem of poor efficacy under the action of CSR, which offers a new avenue in the cancer-related disease treatment.

Tuning the morphology of block copolymer-based pH-triggered nanoplatforms as driven by changes in molecular weight and protocol of manufacturing

The ability to tune size and morphology of self-assemblies is particularly relevant in the development of delivery systems. By tailoring such structural parameters, one can provide larger cargo spaces or produce nanocarriers that can be loaded by hydrophilic and hydrophobic molecules starting ideally from the same polymer building unit. We herein demonstrate that the morphology of block copolymer-based pH-triggered nanoplatforms produced from poly(2-methyl-2-oxazoline)m-b-poly[2-(diisopropylamino)-ethyl methacrylate]n (PMeOxm-b-PDPAn) is remarkably influenced by the overall molecular weight of the block copolymer, and by the selected method used to produce the self-assemblies. Polymeric vesicles were produced by nanoprecipitation using a block copolymer of relatively low molecular weight (Mn ∼ 10 kg.mol−1). Very exciting though, despite the high hydrophobic weight ratio (wPDPA > 0.70), this method conducted to the formation of core–shell nanoparticles when block copolymers of higher molecular weight were used, thus suggesting that the fast (few seconds) self-assembly procedure is controlled by kinetics rather than thermodynamics. We further demonstrated the formation of vesicular structures using longer chains via the solvent-switch approach when the “switching” to the bad solvent is performed in a time scale of a few hours (approximately 3 hs). We accordingly demonstrate that using fairly simple methods one can easily tailor the morphology of such block copolymer self-assemblies, thereby producing a variety of structurally different pH-triggered nanoplatforms via a kinetic or thermodynamically-controlled process. This is certainly attractive towards the development of nanotechnology-based cargo delivery systems.